Relationship between 18F-FDG PET/CT Semi-Quantitative Parameters and International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society Classification in Lung Adenocarcinomas

다국어 초록 (Multilingual Abstract)

Objective: To investigate the relationship between 18F-FDG PET/CT semi-quantitative parameters and the International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) histopathologic classification, including histological subtypes, proliferation activity, and somatic mutations.
Materials and Methods: This retrospective study included 419 patients (150 males, 269 females; median age, 59.0 years; age range, 23.0–84.0 years) who had undergone surgical removal of stage IA–IIIA lung adenocarcinoma and had preoperative PET/CT data of lung tumors. The maximum standardized uptake values (SUVmax), background-subtracted volume (BSV), and background-subtracted lesion activity (BSL) derived from PET/CT were measured. The IASLC/ATS/ERS subtypes, Ki67 score, and epidermal growth factor/anaplastic lymphoma kinase (EGFR/ALK) mutation status were evaluated. The PET/CT semiquantitative parameters were compared between the tumor subtypes using the Mann–Whitney U test or the Kruskal–Wallis test. The optimum cutoff values of the PET/CT semi-quantitative parameters for distinguishing the IASLC/ATS/ERS subtypes were calculated using receiver operating characteristic curve analysis. The correlation between the PET/CT semi-quantitative parameters and pathological parameters was analyzed using Spearman’s correlation. Statistical significance was set at p < 0.05.
Results: SUVmax, BSV, and BSL values were significantly higher in invasive adenocarcinoma (IA) than in minimally IA (MIA), and the values were higher in MIA than in adenocarcinoma in situ (AIS) (all p < 0.05). Remarkably, an SUVmax of 0.90 and a BSL of 3.62 were shown to be the optimal cutoff values for differentiating MIA from AIS, manifesting as pure ground-glass nodules with 100% sensitivity and specificity. Metabolic-volumetric parameters (BSV and BSL) were better potential independent factors than metabolic parameters (SUVmax) in differentiating growth patterns. SUVmax and BSL, rather than BSV, were strongly or moderately correlated with Ki67 in most subtypes, except for the micropapillary and solid predominant groups. PET/CT parameters were not correlated with EGFR/ALK mutation status.
Conclusion: As noninvasive surrogates, preoperative PET/CT semi-quantitative parameters could imply IASLC/ATS/ERS subtypes and Ki67 index and thus may contribute to improved management of precise surgery and postoperative adjuvant therapy.

참고문헌 (Reference)

• 1 Parent EE, "[18F]Fluciclovine PET discrimination between high-and low-grade gliomas" 8 : 67-, 2018
• 2 Satoh Y, "Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy : prognostic value" 270 : 275-281, 2014
• 3 Zhang J, "Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer" 47 : 1137-1146, 2020
• 4 Zhu L, "Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors" 17 : 468-477, 2020
• 5 Nishimukai A, "Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers" 12 : e0184508-, 2017
• 6 Korkmaz U, "The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas" 85 : e254-e260, 2020
• 7 Zugazagoitia J, "The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective : current concepts and future prospects" 6 : S526-S536, 2014
• 8 Fang W, "The IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view" 6 : S552-S560, 2014
• 9 Travis WD, "The 2015 World Health Organization classification of lung tumors : impact of genetic, clinical and radiologic advances since the 2004 classification" 10 : 1243-1260, 2015
• 10 Van Schil PE, "Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification" 39 : 478-486, 2012
• 11 Noguchi M, "Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications" 29 : 15-21, 2010
• 12 Nishii K, "Statistical analysis of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography ground-glass nodule findings" 9 : 279-282, 2018
• 13 Boellaard R, "Standards for PET image acquisition and quantitative data analysis" 50 (50): 11S-20S, 2009
• 14 Chang CC, "SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma" 37 : e189-e195, 2012
• 15 Shao X, "Role of PET/CT in management of early lung adenocarcinoma" 214 : 437-445, 2020
• 16 Incoronato M, "Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype : a PET/MRI study" 45 : 1680-1693, 2018
• 17 Kim YI, "Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the use of FDG PET/CT parameters in prognosis" 210 : 1346-1351, 2018
• 18 Dias-Santagata D, "Rapid targeted mutational analysis of human tumours : a clinical platform to guide personalized cancer medicine" 2 : 146-158, 2010
• 19 Qi L, "Qualitative and quantitative imaging features of pulmonary subsolid nodules : differentiating invasive adenocarcinoma from minimally invasive adenocarcinoma and preinvasive lesions" 11 : 4835-4846, 2019
• 20 Morawitz J, "Prospective correlation of prognostic immunohistochemical markers with SUV and ADC derived from dedicated hybrid breast 18F-FDG PET/MRI in women with newly diagnosed breast cancer" 46 : 201-205, 2021
• 21 Chen HH, "Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer" 264 : 559-566, 2012
• 22 Liao S, "Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer" 39 : 27-38, 2012
• 23 Eriguchi D, "Predictive accuracy of lepidic growth subtypes in early-stage adenocarcinoma of the lung by quantitative CT histogram and FDG-PET" 125 : 14-21, 2018
• 24 Burger IA, "PET quantification with a histogram derived total activity metric : superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients" 41 : 410-418, 2014
• 25 Godoy MC, "Overview and strategic management of subsolid pulmonary nodules" 27 : 240-248, 2012
• 26 Mu W, "Noninvasive decision support for NSCLC treatment using PET/CT radiomics" 11 : 5228-, 2020
• 27 Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 1. 2020" 17 : 1464-1472, 2019
• 28 Sauter AW, "Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT" 53 : 521-529, 2012
• 29 Husby JA, "Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients" 56 : 1191-1198, 2015
• 30 Travis WD, "International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma" 6 : 244-285, 2011
• 31 Lee HJ, "IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma : novel concepts and radiologic implications" 27 : 340-353, 2012
• 32 Castello A, "Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors : the role of 18F-FDG PET/CT" 61 : 821-826, 2020
• 33 Burger IA, "How to assess background activity : introducing a histogram-based analysis as a first step for accurate one-step PET quantification" 35 : 316-324, 2014
• 34 Lee HY, "Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification : prognostic stratification with functional and metabolic imaging biomarkers" 38 : 905-913, 2013
• 35 Chiu CH, "Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan" 6 : 1697-1703, 2011
• 36 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries" 68 : 394-424, 2018
• 37 Xu W, "Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma" 38 : 259-265, 2017
• 38 Shen G, "Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer : a meta-analysis" 59 : 188-195, 2018
• 39 Zhu L, "Correlation between EGFR mutation status and F18-fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma" 10 : 659-664, 2019
• 40 Wang XY, "Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma" 96 : e9365-, 2017
• 41 Nakamura H, "Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography" 87 : 28-33, 2015
• 42 Yip SS, "Associations between somatic mutations and metabolic imaging phenotypes in non–small cell lung cancer" 58 : 569-576, 2017
• 43 Jiang L, "Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status : a systematic literature review and pooled-data analysis" 45 : 870-876, 2019
• 44 Del Gobbo A, "Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas" 68 : 746-751, 2016
• 45 Gormsen LC, "A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT" 9 : 36-, 2019
• 46 Burger IA, "18F-FDG PET/CT of non-small cell lung carcinoma under neoadjuvant chemotherapy : backgroundbased adaptive-volume metrics outperform TLG and MTV in predicting histopathologic response" 57 : 849-854, 2016